Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

MicroTech IPO: Strong Product Portfolio; Small Demand Compared to Other Diabetes Treatment Options

MicroTech Medical IPO: Forecasts and Valuation

MicroTech Medical IPO: Thoughts on First Day Trading

Beijing Airdoc IPO: First Mover in Retina-Based Early Detection and Diagnosis

Abbisko IPO: Some Products Show Good Potential but Too Early to Assess Their Success

Gravity Works As WeWork Doesn't; Now Plan B

Bifurcated Chinese Express Market Developing

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Capital Markets

Shanghai MicroPort MedBot Group / Equity Capital Markets

Shanghai MicroPort MedBot Group (2252 HK)

<a href="https://www.smartkarma.com/entities/shanghai-microport-medbot-group-co-ltd" target="_blank" data-smartkarma-citation="entities:33485:1" rel="noopener">Shanghai MicroPort MedBot Group (MMG HK)</a> is a surgical robot company which designs, develops and commercialises surgical robots to assist in performing complex surgical procedures. The company has filed for an IPO on the Hong Kong Stock Exchange and is expected to raise around US$ 0.7-1bn.Although all of the company’s products are still under development, the company has a strong product line with competitive advantages over the other surgical robots in China and the Chinese market is showing strong potential for implementing surgical robots.MicroPort is the only company globally with a product portfolio covering the five major and fast-growing surgical specialties of laparoscopic, orthopaedic, pan vascular, natural orifice and percutaneous surgical procedures which gives it a strong advantage alongside a number of partnerships.

Shanghai MicroPort MedBot Group (MMG HK) is a surgical robot company which designs, develops and commercialises surgical robots to assist in performing complex surgical procedures. The company has filed for an IPO on the Hong Kong Stock Exchange and is expected to raise around US$ 0.7-1bn.Although all of the company’s products are still under development, the company has a strong product line with competitive advantages over the other surgical robots in China and the Chinese market is showing strong potential for implementing surgical robots.MicroPort is the only company globally with a product portfolio covering the five major and fast-growing surgical specialties of laparoscopic, orthopaedic, pan vascular, natural orifice and percutaneous surgical procedures which gives it a strong advantage alongside a number of partnerships.

MicroPort MedBot IPO: Strong Suite of Surgical Robots Covering Fast-Growing Surgical Specialties